NEW YORK, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) disorders, announced today it was granted new U.S.

2024年1月8日，纽约（环球通讯社）--Anavex Life Sciences Corp.（“Anavex”或“公司”）（纳斯达克：AVXL），一家临床阶段的生物制药公司，开发用于治疗神经退行性疾病和神经发育障碍（包括阿尔茨海默氏病，帕金森氏病，Rett综合征和其他中枢神经系统（CNS）疾病）的差异化疗法，今天宣布它被授予新的美国。

Patent No. 11,839,600 entitled “NEURODEVELOPMENTAL DISORDER THERAPY” from the United States Patent and Trademark Office (USPTO) for its patent application number 17/890,083. Anavex’s newest patent expands coverage of ANAVEX®2-73 (blarcamesine) therapy to ameliorate various conditions associated with loss-of-function mutations of the gene encoding methyl-CpG binding protein (MeCP2).

美国专利商标局（USPTO）的专利号为11839600，其专利申请号为17/890083，标题为“神经发育障碍疗法”。Anavex的最新专利扩大了Anavex®2-73（blarcamesine）疗法的覆盖范围，以改善与编码甲基CpG结合蛋白（MeCP2）的基因功能丧失突变相关的各种疾病。

The patent claims protect use of ANAVEX®2-73 (blarcamesine) to address a range of symptoms exhibited by patients suffering from neurodevelopmental and neurological conditions related to McCP2, such as abnormal breathing, abnormal cardiac function, abnormal feeding, abnormal choking, weight gain failure, abnormal sleep, seizures, abnormal gadolinium-enhancing lesions.

该专利要求保护ANAVEX®2-73（blarcamesine）的使用，以解决患有与McCP2相关的神经发育和神经系统疾病的患者所表现出的一系列症状，例如呼吸异常，心脏功能异常，进食异常，窒息异常，体重增加失败，睡眠异常，癫痫发作，钆增强异常病变。

Such conditions are frequently associated with diseases such as Rett syndrome, autism spectrum disorder, multiple sclerosis, cerebral palsy, Angelman syndrome, Williams syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, Smith-Magenis syndrome, non-syndromic mental retardation, idiopathic neonatal encephalopathy, and idiopathic cerebral palsy.

此类疾病通常与疾病有关，例如Rett综合征，自闭症谱系障碍，多发性硬化症，脑瘫，Angelman综合征，Williams综合征，未另行说明的普遍性发育障碍（PDD-NOS），儿童崩解障碍，Smith-Magenis综合征，非综合征性智力低下，特发性新生儿脑病，和特发性脑瘫。

This newest patent is expected to remain in force at least until January 2037, not including any patent term extension. “This new patent on use of ANAVEX®2-73 (blarcamesine) in ameliorating difficult symptoms as.

这项最新专利预计将至少持续到2037年1月，不包括任何专利期限的延长。“这项关于使用ANAVEX®2-73（blarcamesine）改善as困难症状的新专利。